Cardiology

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Your daily dose of the clinical news you may have missed.

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.

Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.

Your daily dose of the clinical news you may have missed.

How are you managing your patients with resistant or refractory hypertension? How do your strategies align with current guidelines? Try these 9 questions and find out.

Hypertension that is resistant or refractory to treatment increases the risk of comorbidity and cardiovascular risk. Click through this at-a-glance review of key issues.

Your daily dose of the clinical news you may have missed.

New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.

Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.

Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.

ESC 2024: Cannabis, opioid, and MDMA use were most strongly tied to cardiovascular event risk, according to a new study.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

In secondary CVD prevention, low/moderate-dose statins plus ezetimibe were superior to high-dose statin for reducing biomarkers, myalgias but did not reduce MACE.

Anila Chadha, MD, talks to Patient Care about how antiobesity medications can aid in reducing CVD risk in patients with obesity.

Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.

White coat and masked hypertension can be elusive and dangerous. Click through a topline look at recommendations from the 2017 ACC/AHA hypertension guidelines.